Compare Heron Therapeutics Inc (HRTX) vs Magnolia Oil & Gas Corporation Class A Common Stock (MGY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Magnolia Oil & Gas Corporation Class A Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $70.25M), while Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.69B). The key difference: Magnolia Oil & Gas Corporation Class A Common Stock is far larger — about 95.2× Heron Therapeutics Inc's market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.66% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days on average.
| HRTX | MGY | |
|---|---|---|
Market Cap | $70.25M | $6.69B |
Volume | 2,092,253 | 2,677,107 |
Sector | Health | Energy |
52-Week High | $1.49 | $32.36 |
52-Week Low | $0.27 | $21.24 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $176.99M | $6.80B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $20.20 million on $154.90 million revenue in 2025, with a negative net income margin of -22.52%. Recent Q2 2026 earnings missed expectations, posting a loss of $0.03 per share versus an expected loss of $0.005. Analyst consensus remains strongly positive with 17 buy ratings out of 19 total.
The outlook is mixed; strong analyst support and improving cash flow trends in 2026 suggest potential, but persistent losses and high valuation multiples like EV/EBITDA of 34.03 pose significant risks. Investment opportunity hinges on future profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →
